))
Breaking Barriers in Drug Development: Dr. David E. Martin CEO TrippBio
Fetch error
Hmmm there seems to be a problem fetching this series right now.
Last successful fetch was on November 09, 2024 01:21 (
What now? This series will be checked again in the next hour. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 421501315 series 3563546
A tartalmat a Donald Davis, PhD and Don Davis biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Donald Davis, PhD and Don Davis vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.
In this episode of the Life Science Success podcast, we have Dr. David E. Martin, the President and CEO of TrippBio, Inc., a distinguished translational scientist with over 30 years of experience in drug development. Dr. Martin has led numerous groundbreaking projects and is here to share his insights on the future of therapeutic advancements.
🚀 Book a FREE Digital Marketing strategy Session 👉 https://link.cxnector.com/widget/book...
Introduction of Dr. David E. Martin: Dr. David E. Martin, with over 30 years in drug development, joins Don on the "Life Science Success" podcast to discuss his career and insights into therapeutic advancements.
Dr. Martin's Background: Dr. Martin, trained as a pharmacist during the AIDS epidemic, developed a passion for infectious diseases and clinical research, which led him into life sciences. His career is marked by his role as a translational scientist focusing on groundbreaking projects.
Professional Achievements: He highlights his work with HIV RNA as a surrogate marker in drug development, detailing his involvement in pioneering studies that validated PCR technology in clinical trials. This work significantly contributed to how drug efficacy is evaluated, particularly concerning HIV treatments.
Role at TrippBio: As the CEO of TrippBio, Dr. Martin discusses the company's focus on developing drugs targeting host factors rather than the pathogens themselves, reducing the likelihood of resistance. TrippBio is exploring treatments for major respiratory viruses using this novel approach.
Vision and Challenges: Dr. Martin shares his vision for TrippBio to develop a universal treatment for major respiratory infections and discusses the challenges small biotechs face, especially in securing funding and managing innovative research within tight budgets.
100 epizódok
Megosztás
